Close
Jane Kinghorn named as one of BioBeat’s 50 Movers and Shakers 2018
1 November 2018
A new report has named Dr Jane Kinghorn (Director, UCL Translational Research Office) as one of 50 female leaders in healthcare business in the UK.
A new report has named Dr Jane Kinghorn (Director, UCL Translational Research Office) as one of 50 female leaders in healthcare business in the UK. Produced by BioBeat, 50 Movers and Shakers in BioBusiness 2018 emphasises the current role of women in leading, inspiring and innovating to ensure new technologies and treatments continue to improve UK research, health and society.
Dr Kinghorn is responsible for a team of highly experienced applied scientists tasked with establishing the organisational culture, capability and processes necessary to deliver the UCL and BRCs mission of "Accelerating translation for health and wealth". UCL’s Translational Research Office builds on an increasingly vibrant translational culture across the School of Life and Medical Sciences and the wider university community by providing integrated support for translational research, industrial partnerships and drug discovery.
BioBeat Founder Miranda Weston-Smith commented: “Congratulations to the outstanding women leaders who are recognised as the 50 Movers and Shakers in BioBusiness 2018. They are changing what is possible for the benefit of humanity and helping to build a more inclusive, responsive healthcare ecosystem – whether that’s by developing revolutionary products, shaping bioscience through investment, accelerating the innovation pipeline, transforming patient access to healthcare or supporting innovation from concept to market.”
A collaborative innovation platform for healthcare entrepreneurs and leaders, BioBeat has celebrated 50 Movers and Shakers in BioBusiness each year since 2014. It champions collaboration by bringing together scientific and business expertise, and creating a forum for investors and entrepreneurs to partner, which ultimately brings benefits to patients in the form of innovative new treatments.